Selank

Selank is a synthetic heptapeptide developed in Russia, designed to modulate stress, anxiety, and cognitive function by influencing neurotransmitters and immune pathways.

Selank is a synthetic analog of tuftsin, a naturally occurring immune peptide, consisting of seven amino acids with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) developed at the Institute of Molecular Genetics in Moscow during the 1990s. It is classified as a neuropeptide, meaning it interacts with the nervous system to influence brain function and behavior. Unlike traditional anxiolytics, Selank is designed to reduce anxiety and improve cognitive performance without sedation, dependency, or cognitive impairment.

Quickstart Highlights

Selank is a synthetic heptapeptide analog of tuftsin with demonstrated anxiolytic and anti-asthenic (energy-boosting) properties in human clinical trials^[1][2]. In Russian studies, intranasal Selank produced anxiolytic effects comparable to benzodiazepines without sedation or dependence potential^[1].

How It Works

Selank is a synthetic analog of the immunomodulatory peptide tuftsin, consisting of the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. In Russian clinical trials for anxiety disorders and neurasthenia, intranasal Selank produced anxiolytic effects comparable to benzodiazepines while also providing anti-asthenic (energy-boosting) benefits without sedative side effects or dependence potential^[1][2]. Preclinical studies in primates demonstrated that intranasal Selank eliminated fear and anxiety behaviors with long-term stabilizing effects on neurobehavior^[4]. Rodent studies confirmed robust anxiolytic efficacy comparable to classical tranquilizers^[5]. While most published human data utilized intranasal dosing (the original formulation), subcutaneous administration has shown effectiveness in research settings with consistent absorption and ease of dose measurement^[3]. A 14-day continuous course was well-tolerated and effective in human trials^[2], and even high-dose applications have been explored for conditions such as attenuating opioid withdrawal symptoms in animal models^[5].

Potential Benefits & Side Effects

Observations from clinical and preclinical literature.

• Produces anxiolytic effects comparable to benzodiazepines in human clinical trials without sedation or dependence risk^[1].
• Provides anti-asthenic (energy-boosting) benefits alongside anxiety reduction^[2].
• Induces lasting neurobehavioral changes; primate studies showed elimination of fear/anxiety behaviors with long-term stabilizing effects^[4].
• Generally well tolerated in clinical studies; a 14-day continuous course was well-tolerated and effective in human trials^[2].
• Occasional mild injection-site reactions (redness, minor irritation) may occur with subcutaneous administration; proper site rotation minimizes this risk.
• Lacks sedative side effects typical of classical anxiolytics, allowing for daytime use without impairment^[1].
• Has been explored at higher doses for experimental applications such as attenuating opioid withdrawal symptoms, indicating a wide therapeutic range^[5].

References

• PubMedClinical trial of Selank for generalized anxiety disorder (intranasal, human study)
• PubMedSelank for neurasthenia: 14-day clinical trial demonstrating anxiolytic and anti-asthenic effects (human study)
• Hindawi BioMed ResearchIntranasal Selank administration review: neurobehavioral effects and clinical applications (review article)
• SpringerPrimate studies: intranasal Selank eliminates anxiety behaviors with long-term effects (preclinical)
• SpringerSelank attenuates opioid withdrawal symptoms in animal models (preclinical dosing study)
• CDCVaccine administration best practices: subcutaneous injection technique and site selection
• Cleveland ClinicSubcutaneous injection guide: technique, sites, and rotation principles
• NCBI BookshelfClinical procedures: injection preparation, aseptic technique, and administration standards
• CDCInjection safety guidelines: single-use devices, sharps disposal, and preventing unsafe practices
• NIBSCPeptide storage guidelines: lyophilized and reconstituted stability considerations
• PMCPharmacologic review: subcutaneous drug delivery and absorption considerations